Results 11 to 20 of about 27,373 (254)

Aliskiren, tadalafil, and cinnamaldehyde alleviate joint destruction biomarkers; MMP-3 and RANKL; in complete Freund's adjuvant arthritis model: Downregulation of IL-6/JAK2/STAT3 signaling pathway

Saudi Pharmaceutical Journal, 2020
Rheumatoid arthritis (RA) is an autoimmune inflammatory disease, which is accompanied by progressive joint damage and disability. The intolerability of conventional antirheumatic drugs by some patients necessitates the search for effective antirheumatic ...
Amany A. Azouz, Esraa Saleh, Ali A. Abo-Saif   +2 more
doaj   +1 more source

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). [PDF]

, 2020
OBJECTIVES: To investigate the efficacy and safety of ixekizumab for up to 52 weeks in two phase 3 studies of patients with active radiographic axial spondyloarthritis (r-axSpA) who were biological disease-modifying antirheumatic drug (bDMARD)-naive ...
Baraliakos, X., Bertram, C.C., Bosch, F. van den, Carlier, H., COAST-V Study Grp, COAST-W Study Grp, Deodhar, A., Dougados, M., Ermann, J., Gallo, G., Gensler, L.S., Heijde, D. van der, Landewe, R., Li, X.Q., Maksymowych, W.P., Sieper, J., Tomita, T., Walsh, J.A., Wei, J.C.C., Zhao, F.Y.   +19 more
core   +3 more sources

Updated American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty 2022

Научно-практическая ревматология, 2023
The article presents updated guidelines developed by the American College of Rheumatology and the American Association of Hip and Knee Surgeons on the perioperative treatment of patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic ...
V. N. Amirjanova, M. A. Makarov, A. E. Karateev, A. E. Khramov, S. V. Maglevaniy, A. V. Rozov, V. A. Nesterenko, E. L. Nasonov   +7 more
doaj   +1 more source

CARDIOVASCULAR DISEASES IN RHEUMATOID ARTHRITIS: LATEST DATA

Научно-практическая ревматология, 2016
The paper gives the latest data on the impact of traditional cardiovascular risk factors, chronic inflammation, antirheumatic therapy (disease-modifying antirheumatic drugs and biological agents) on the cardiovascular system.
T. V. Popkova, D. S. Novikova, E. L. Nasonov   +2 more
doaj   +1 more source

A case of essential thrombocythemia and ankylosing spondylitis treated with a combination of anagrelide, disease-modifying antirheumatic drugs, and etanercept [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2016
Introduction. A high platelet count, or thrombocytosis, is either a reactive process or a result of a myeloproliferative disorder. Ankylosing spondylitis is a chronic inflammatory rheumatic disease affecting the spine and sometimes peripheral ...
Zeremski Vanja, Savić Aleksandar, Ilić Tatjana, Milošević Ivana, Maksimović Marina, Vučković Biljana   +5 more
doaj   +1 more source

Rheumatoid arthritis [PDF]

, 2016
Rheumatoid arthritis is a chronic inflammatory joint disease, which can cause cartilage and bone damage as well as disability. Early diagnosis is key to optimal therapeutic success, particularly in patients with well-characterised risk factors for poor ...
Aletaha, Daniel, McInnes, Iain B., Smolen, Josef S.   +2 more
core   +1 more source

Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. [PDF]

, 2016
IntroductionTofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Tofacitinib monotherapy was previously shown to inhibit structural damage, reduce clinical signs and symptoms of RA, and improve physical ...
DeMasi, Ryan, Fleischmann, Roy M, Huizinga, Tom WJ, Kavanaugh, Arthur F, Kwok, Kenneth, van Vollenhoven, Ronald F, Wilkinson, Bethanie   +6 more
core   +11 more sources

Use of the painDETECT tool in rheumatoid arthritis suggests neuropathic and sensitization components in pain reporting. [PDF]

, 2014
Rheumatoid arthritis (RA) is an inflammatory autoimmune condition typified by systemic inflammation targeted toward synovial joints. Inhibition of proinflammatory networks by disease-modifying antirheumatic drugs, eg, methotrexate and biologic therapies,
Ahmed, S, Harrison, A, Magan, T, Sofat, N, Vargas, M   +4 more
core   +2 more sources

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. [PDF]

, 2019
ObjectiveTo evaluate the efficacy of denosumab in suppressing joint destruction when added to conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy in patients with rheumatoid arthritis (RA).MethodsThis was a multi-centre ...
Genant, Harry K, Nitta, Takaya, Okubo, Naoki, Soen, Satoshi, Takeuchi, Tsutomu, Tanaka, Sakae, Tanaka, Yoshiya, van der Heijde, Désirée, Yamanaka, Hisashi, Yoneda, Toshiyuki   +9 more
core   +2 more sources

Effects of antirheumatic agents on cytokines [PDF]

Seminars in Arthritis and Rheumatism, 1996
A review of the literature concerning the effects of traditional antirheumatic drugs on cytokines and the cytokine and anticytokine approaches already used in the therapy of rheumatoid arthritis (RA) is presented. Many antirheumatic drugs are capable of cytokine modulation in vitro. Corticosteroids inhibit the transcription of a broad spectrum of genes
Barrera Rico, P., Boerbooms, A.M.T., Putte, L.B.A. van de, Meer, J.W.M. van der   +3 more
openaire   +4 more sources